Antitumour necrosis factor-α therapy modulates angiopoietin-2 serum levels in non-diabetic ankylosing spondylitis patients

scientific article published on 12 March 2013

Antitumour necrosis factor-α therapy modulates angiopoietin-2 serum levels in non-diabetic ankylosing spondylitis patients is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1136/ANNRHEUMDIS-2012-203169
P698PubMed publication ID23482472

P50authorRodrigo OchoaQ44738492
Ricardo BlancoQ73343789
P2093author name stringMiguel A González-Gay
Javier Llorca
Carlos González-Juanatey
Fernanda Genre
José A Miranda-Filloy
Beatriz Carnero-López
Javier Rueda
Raquel López-Mejias
P433issue7
P921main subjectankylosing spondylitisQ52849
P304page(s)1265-1267
P577publication date2013-03-12
P1433published inAnnals of the Rheumatic DiseasesQ4767876
P1476titleAntitumour necrosis factor-α therapy modulates angiopoietin-2 serum levels in non-diabetic ankylosing spondylitis patients
P478volume72

Reverse relations

cites work (P2860)
Q37686803Adipokines, biomarkers of endothelial activation, and metabolic syndrome in patients with ankylosing spondylitis.
Q34081242Cardiovascular involvement in autoimmune diseases
Q34250990IGF-1 and ADMA levels are inversely correlated in nondiabetic ankylosing spondylitis patients undergoing anti-TNF-alpha therapy
Q33747796Patients with ankylosing spondylitis and low disease activity because of anti-TNF-alpha therapy have higher TRAIL levels than controls: a potential compensatory effect
Q37551794Serum levels of three angiogenic factors in systemic lupus erythematosus and their clinical significance

Search more.